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UTILITY OF REPEAT SCREENING FOR ASYMPTOMATIC BACTERIURIA IN 
PREGNANCY 
Sara Whetstone, Stephen Thung, and Jessica Illuzzi.  Department of Obstetrics, 
Gynecology, and Reproductive Sciences, Yale University, School of Medicine, New 
Haven, CT. 
 
Asymptomatic bacteriuria (ASB) during pregnancy is associated with an increased risk of 
developing pyelonephritis.  The objectives of our study were to determine the incidence of ASB 
throughout the first two trimesters of pregnancy and to compare the cost effectiveness of 
performing repeat screening with a single screening strategy for ASB to prevent pyelonephritis.  
In this prospective cohort study, 206 pregnant women at an urban academic obstetric clinic 
provided urine for culture at monthly prenatal visits, and the incidence of ASB was calculated at 
4 weeks intervals in the first and second trimesters.  Descriptive statistics were calculated and 
used as baseline estimates in the cost-effectiveness analysis.  Decision and cost-effectiveness 
analyses were performed. In the decision analysis, three strategies were compared: (1) no 
screening; (2) screening for ASB once in the first trimester; and (3) screening for ASB once in the 
first trimester and once between 18 and 22 weeks gestational age (GA).     
9.71% of women were positive on initial screening culture for ASB.  Among women with an 
initial negative culture, the incidence rate of ASB was 0% at less than 14 weeks GA, 1.1% 
between 14-18 weeks GA, 4.2% between 18-22 weeks GA, and 1.8% at greater than 22 weeks 
GA.  The proportion of women identified with ASB on initial culture did not differ statistically 
from the proportion identified on repeat culture (McNemar’s test, p-value > 0.05).  In the 
decision analysis, a policy of routine screening in the first and second trimester (2 urine culture 
strategy) was the dominant strategy compared to no screening and a single culture strategy.  
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Understanding Asymptomatic Bacteriuria 
Asymptomatic bacteriuria (ASB) or asymptomatic urinary tract infection signifies 
bacteria in the urine in the absence of urinary tract specific symptoms.  ASB occurs 
across populations, especially amongst women, diabetic patients, elderly individuals, 
and persons with spinal cord injury.  The progression of ASB to more severe, 
symptomatic disease has not been validated in many groups of patients, and 
consequently screening for and treatment of ASB is not uniformly recommended.  The 
physiologic changes of pregnancy, however, put pregnant women at increased risk for 
ascending infection.  For this reason, the Infectious Disease Society of America (IDSA) 
formally advocates for ASB screening and treatment among two groups of patients:  
pregnant women and individuals undergoing urologic procedures.(1)   
The microbiologic definition of ASB relies upon the urine culture, the threshold of 
greater than 100,000 CFU/mL, and a confirmatory repeat culture.   This triad has been 
validated to distinguish true bacteriuria from contamination.  The urine culture, despite 
its expense, is considered the gold standard in the detection of ASB as other urine 
screening tests perform poorly in comparison.  Gram staining would be the most likely 
alternative to urine culture given its high sensitivity of 90% and specificity of 88%; 
however, it is a time consuming process and a relatively expensive method in an office 
setting.(2, 3)  Urinalysis and urine dipstick, while more rapid to perform, are considered 
to be inadequate screening tools in pregnancy given their low sensitivities.  Urinalysis 
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for pyuria detects only 25-67% of samples identified as bacteriuric by culture, and urine 
dipstick for leukocyte esterase or nitrite has a similar sensitivity in the range of 50-
73%.(2-6)  Thus, the urine culture remains the test of choice as no other currently 
available test has sufficiently high sensitivity and negative predictive value for ASB. 
Prior to the 1950s there was no specific threshold in terms of bacterial number to 
differentiate contamination from true bacteriuria.  Kass determined that a bacterial 
count of at least 100,000 CFU/mL in a voided specimen was confirmed in greater than 
95% of subjects by a catherized specimen.(7, 8)  Lower colony counts often were not 
confirmed by catherization and represented contamination of the urine specimen by 
vaginal and external flora during sample collection.  In fact, if a sample had fewer than 
100,000 CFU/mL, the probability was approximately 4% that the subsequent specimen 
from the same patient would culture more than 100,000 CFU/mL.(7, 9)    Interestingly in 
practice today, many clinicians cite colony counts well below 100,000 CFU/mL as 
justification for the use of antibiotics in pregnancy given the risks of untreated ASB.  (see 
Section “Asymptomatic Bacteriuria in Pregnancy”). 
The definition of true ASB as defined by IDSA requires at least two consecutive voided 
urine specimens with greater than 100,000 CFU/mL of the same bacterial strain.(1)  Kass 
demonstrated that bacteriuria was confirmed in only 80% of women if only one voided 
urine culture was used to diagnose ASB but was confirmed in greater than 95% of 
women if two previous specimens showed bacteriuria.(8, 10)   In practice today, a 
single-voided midstream urine with greater than 100,000 CFU/mL is accepted as an 
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adequate alternative definition of ASB.(11)  We suspect that practitioners find obtaining 
repeat specimens from their patients impractical as prenatal visits occur only once a 
month in early pregnancy.   
Based upon the aforementioned definition of ASB, its prevalence amongst pregnant 
women has been reported to range from two to ten percent.(12, 13)  Similar prevalence 
rates are reported in non-pregnant women, and accordingly pregnancy is not believed 
to be a risk factor for its development.(12)   The microbiology of ASB in pregnancy 
reflects the organisms isolated from non-pregnant bacteriuric women.  Escherichia coli 
is the most common pathogen with an estimated prevalence of 65 to 80%, followed by 
other gram-negative organisms such as Proteus mirabilis, Klebsiella pneumoniae and 
Enterobacter.(11, 14)  Gram-positive bacteria like Enterococcus, Streptococcus 
agalactiae, and Staphylococcus saprophyticus have been identified as causing 
bacteriuria, particularly in the last trimester, and there is increasing recognition of 
fastidious organisms, such as Ureaplasma urealyticum, as urinary pathogens.(15-17) 
Increased prevalence of ASB is associated with multiparity, multiple sexual partners, 
increasing age, and low socio-economic status.(18) Women with diabetes mellitus and 
sickle cell disease or trait have also been identified as individuals who have higher rates 
of bacteriuria due to alterations in genitourinary tract function.  Individuals with chronic 
diseases that impair voiding or that involve long-term indwelling catheters have even 




Asymptomatic Bacteriuria in Pregnancy 
Women are anatomically predisposed to bacterial colonization of the bladder– the 
external third of the urethra is colonized by vaginal flora and sexual intercourse 
increases the risk of urinary infection.  Changes in the genitourinary tract during 
pregnancy predispose women to pyelonephritis; over 80% of pyelonephritis cases occur 
in the second and third trimesters, a period of time when physiologic adaptations of 
pregnancy promote greater urinary stasis and bacterial proliferation.(19)  The most 
notable of these changes is the dilatation of the collecting system.  Progesterone 
induces smooth muscle relaxation, leading to decreased ureteral peristalsis and 
tone.(20)  Additionally, the enlarging uterus extends beyond the pelvis in mid-pregnancy 
to compress the ureters at the pelvic brim; interestingly, the right ureter, the side where 
pyelonephritis more frequently develops, experiences greater dilation due to 
dextrorotation of the uterus, while the left ureter is cushioned by the sigmoid colon.(21)  
The hypertrophy of Waldeyer’s sheath, the longitudinal muscle at the lower ureter, may 
contribute to further dilatation proximally by functionally compressing the lower 
ureter.(20) As a result of anatomic, physiologic, and hormonal changes, the upper 
collecting system can accommodate 200 to 300 mL of urine and becomes a potential 
reservoir for infection.(20)   
Other changes may also increase pregnant women’s susceptibility to urinary tract 
infections.  Like the ureters, the bladder experiences a progesterone-induced decrease 
in tone and subsequent increase in capacity; the expanding uterus, however, 
simultaneously displaces the bladder superiorly and anteriorly, causing it to flatten out 
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and decrease its capacity.  Despite conflicting results about the bladder’s capacity in 
pregnancy, some authors speculate an anatomic change occurs that renders the bladder 
more susceptible to infection; its flaccidity may also contribute to vesicoureteral reflux 
and increase the likelihood of ascending infection.(22, 23)   
Hormonal factors of pregnancy may additionally alter susceptibility to infection.  In 
experimental settings, rats who received diethylstilbestrol were more likely to 
experience renal parenchymal infection with E coli, and urine from women who used 
oral contraception had an increased rate of in vitro bacterial growth.(24, 25)   In 
addition, the glucosuria and aminoaciduria of pregnancy, resulting from decreased 
fractional absorption in the kidney, facilitate bacterial proliferation in urine, an already 
excellent growth medium. The net effect of these changes is to increase the likelihood 
of a symptomatic urinary tract infection to develop during pregnancy. 
Bacteriuria has been shown to be the most significant factor associated with 
development of acute pyelonephritis in pregnancy.(9, 10)  The risk of pyelonephritis 
ranges from 20-40% among pregnant women with untreated ASB.(10) (12)  Therefore, 
women with ASB detected in pregnancy have a 20-30-fold risk of developing acute 
pyelonephritis in comparison to pregnant women without bacteriuria.(14, 26, 27)    The 
relationship between bacteriuria and acute pyelonephritis is substantiated by the fact 
that the bacterial species cultured from women with acute pyelonephritis mirror those 
cultured from women with bacteriuria.  E coli is the most common pathogen amongst 
women with acute pyelonephritis, accounting for greater than 70% of cases.(11, 19)   
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Today, in the era of screening and treatment of ASB, the overall incidence of 
pyelonephritis in pregnancy is relatively low, at one to two percent.(21)  Nonetheless, 
pyelonephritis continues to be the most common serious medical complication of 
pregnancy and genitourinary complications account for approximately 10% of antenatal 
admissions to the hospital.(28)  Acute pyelonephritis in pregnancy also results in 
significant maternal and fetal morbidity.  At the time of diagnosis, approximately 20% of 
women have concurrent bacteremia, and a similar percentage of women experience 
multi-organ system dysfunction.(19, 29, 30)   It is believed that endothelial activation 
and subsequent capillary fluid extravasation lead to alterations in blood pressure, renal 
function, and gas exchange.(21)   These vascular changes cause intravascular depletion, 
and hypotension is fairly common(21)  Diminished renal function, albeit often transient, 
occurs in 5% of women, although in the past, 10-20% of women were reported to 
experience kidney injury.(19, 30)  Twenty percent of pregnant women with 
pyelonephritis develop anemia during their infection, attributed to endotoxin-
stimulated hemolysis.(31)  Those women who unfortunately develop severe sepsis are 
at risk for activation of coagulation pathways.   The most concerning complication is the 
development of acute pulmonary injury from suspected endotoxin-mediated damage to 
alveolar capillary membranes.  The resultant respiratory insufficiency, seen in 2-8% of 
women, ranges in severity from an increased oxygen requirement to severe acute 
respiratory distress syndrome requiring intubation and mechanical ventilation.(32, 33)   
Urosepsis, or proliferation of the uropathogen within the bloodstream, is the leading 
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cause of septic shock during pregnancy, and one study reported that nearly 10% of 
women with pyelonephritis required admission to the obstetric intensive care unit.(19)   
Prior to the 1940’s and before the use of antibiotics, acute pyelonephritis was clearly 
associated with a 20-50% incidence of preterm birth. (27, 34, 35)  The mechanisms for 
preterm labor resulting from pyelonephritis have not been completely elucidated but 
are presumed to be related to endotoxin-stimulated uterine activity or bacterial 
production of phospholipase A2.   A recent large cohort study (2005) found that preterm 
birth occurred in only 5% of women with acute pyelonephritis who received antibiotic 
therapy, a rate comparable to that of the general obstetric population today.(19) The 
association between bacteriuria and preterm birth is more controversial.  Kass initially 
reported an increased risk of preterm birth in women with persistent bacteriuria, a risk 
that could be modified by the use of antibiotics throughout gestation.(9, 10)  
Subsequent studies of various designs showed conflicting results, with most failing to 
demonstrate a relationship between preterm birth and ASB.  Those studies that 
revealed an excess rate of preterm delivery with bacteriuria were often statistically 
underpowered or did not show that treatment altered the rate of prematurity.(12) A 
meta-analysis of 17 cohort studies found a strong association between ASB and low 
birth weight/preterm delivery and additionally demonstrated that antibiotic treatment 
reduced the rate of low birth weight.(36)  Critiques of the meta-analysis cite poor 
methodological quality of the studies included in the analysis, inability to define a 
mechanism in which bacteriuria causes preterm labor, and failure to control for 
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infections outside the urinary tract, particularly those in the cervix and vagina, that may 
respond to antibiotics and that have been linked to prematurity.(12, 35) If bacteriuria 
does contribute to preterm delivery, as Whalley stated, it accounts for a very small 
proportion and ASB treatment will minimally affect the rate of preterm birth.(12) 
Screening and Treatment of Asymptomatic Bacteriuria in Pregnancy 
There is convincing evidence that antibiotic treatment of ASB is effective in preventing 
the well-established adverse maternal outcomes, such as pyelonephritis, sepsis, and 
ARDS.  A systematic review of 14 studies comparing antibiotic treatment with no 
treatment or placebo found that antibiotic treatment was effective in clearing ASB (OR 
0.07, 95% CI 0.05-0.10) and was associated with a reduced incidence of pyelonephritis 
(OR 0.24, 95% CI 0.19-0.32).(35)  In the literature, there is no single antibiotic that is 
optimal in the treatment of ASB, and no study has had the power to determine the 
optimal duration of therapy; therefore, current recommendations encourage empiric 
treatment of ASB.  Even with antibiotic treatment, it should be noted that the 
recurrence rate of ASB is reported to be 20-30%.(12)   
Based on the evidence, screening for ASB in pregnancy has been incorporated into 
prenatal care in most developed countries for decades.  Trials have repeatedly shown 
that screening and treatment of ASB has substantially decreased the incidence of 
pyelonephritis in pregnancy.(35)  Implementation of such programs in Spain resulted in 
a decrease in incidence of pyelonephritis from 1.8% to 0.6% and in Turkey from 2.1% to 
0.5%.(37, 38) In the United States, the incidence of pyelonephritis has declined from 3-
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4% in the 1970s to 1-2% with universal screening.(39, 40)   When compared with a 
policy of no screening, screening for and treatment of ASB in pregnancy is regarded to 
be cost-beneficial.(41)   Another study showed a single screening culture in first 
trimester to be cost-effective if the prevalence of bacteriuria is greater than 2% and the 
risk of pyelonephritis in bacteriuric women is greater than 13%.(42)   
Accordingly, the United States Preventive Services Task Force (USPSTF), American 
College of Obstetricians and Gynecologists (ACOG), American Academy of Pediatrics 
(AAP), American Academy of Family Physicians (AAFP), and IDSA recommend screening 
for ASB in early pregnancy.(43, 44)  Some of these national organizations even explicitly 
state that screening should occur at 12 to 16 weeks gestational age (GA) or at the first 
prenatal visit if after that time.   The timing of screening is based on reports that the 
majority of bacteriuria was present by the second month of gestation.(10)  Moreover, 
initial published studies reported that pyelonephritis occurred only amongst women 
identified with ASB at the initial visit and thus it followed that women should be 
screened when they first presented for prenatal care.(8, 10) Later studies contradicted 
these earlier reports and showed that approximately one to two percent of pregnant 
women with negative initial cultures develop pyelonephritis.(1, 14, 26, 27)  This latter 
figure has two interesting implications, the first being that it is likely that a proportion of 
women develop bacteriuria later over the course of pregnancy despite an initial 
negative culture.  This bacteriuria is most likely unrecognized and untreated leading in 
some cases to pyelonephritis.  The second is that the absolute number of women who 
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initially test negative but go on to develop pyelonephritis (1-2%) is what would be 
expected if 2-10% subsequently developed ASB and were not treated   (20-40% of 2-10% 
or 0.4-4%).  This should raise concern that the rate of ASB may be similar in first 
trimester and second trimesters.  An example will help to illustrate this second point 
(see Table 1).  In a cohort of 1000 pregnant women with a 6% rate of ASB at initial 
culture (60 women), twelve women will develop pyelonephritis if untreated, assuming a 
20% risk of pyelonephritis.  Of the 940 women with initial negative cultures, 
approximately fourteen women will develop pyelonephritis, given a 1.5% incidence rate 
of pyelonephritis over the course of pregnancy.   Accordingly, current screening 
procedures have been cited to only detect 40-70% of women who develop 
pyelonephritis.(45-47)    
Table 1. Percentage of women predicted to develop pyelonephritis identified by 
current screening methods using published estimate ranges in a cohort of 1000 (12, 41, 
44) 
 Low Estimate Middle Estimate High Estimate 
Prevalence of ASB at initial culture 2% 6% 10% 
Risk of pyelonephritis 20% 20% 20% 
Incidence of pyelonephritis among 
initial culture negative women 
1% 1.50% 2% 
Number of women with positive initial 
culture who develop pyelonephritis 
(assuming no treatment)A 
4 12 20 
Number of women with negative initial 
culture who develop pyelonephritisB 
9.8 14.1 18 
Percentage of women who develop 
pyelonephritis who are detected by 
screening at initial visit
C
 
29.0% 46.0 % 52.6% 
A
Number of women with positive initial culture who develop pyelonephritis (assuming no treatment) =  population of women (N) x 
rate of ASB x risk of pyelonephritis if no treatment 
B
Number of women with negative initial culture who develop pyelonephritis = (N - number of women with ASB at first culture) x 
1% 
C
Percentage of women who develop pyelonephritis who are detected by screening at initial visit = Number of women with positive 




Although screening programs have been commended for their successes, there are gaps 
in the published literature which limit current recommendations.  The IDSA and USPSTF, 
among others, have reported that no study has fully addressed the optimal timing for 
the initial urine culture.(35, 44, 48)  A Swedish study reported that screening at 16 
weeks would be the optimal time to maximize detection of ASB as well as the number of 
bacteriuria-free weeks in pregnancy.(49)   In the United States, there has been no 
systematic effort to study the ideal time for initial ASB testing despite the fact that 
nearly 30 to 60% of women who develop symptomatic urinary tract infection in 
pregnancy are not identified by initial screening measures.    The benefit from additional 
screening in pregnancy is unknown.  In fact, Nicolle et al. write, “It has not been 
evaluated whether a second screening culture obtained in later pregnancy would 
further reduce the risk of pyelonephritis and its complications, and remain cost-




STATEMENT OF PURPOSE 
Given the remaining questions about ASB screening, the aims of the study are to 
calculate the incidence rate of ASB at various times in pregnancy using a prospective 
cohort of women and to evaluate the cost-effectiveness of performing repeat cultures 
for ASB in pregnancy.   The ultimate goal of the research is to inform cost-effective 
evidence-based guidelines for the timing of asymptomatic bacteriuria screening in order 
to optimally reduce the incidence of pyelonephritis and its associated maternal 
morbidity.   It is our hypothesis that a greater proportion of women will develop ASB 
after an initial negative culture than previously reported in the literature, and thus 
repeat screening will be cost-effective given the high costs of managing acute 





The study design consisted of two components to determine the cost-effectiveness of 
repeat screening for ASB in pregnancy.  As the literature lacked detailed data on the 
incidence of ASB throughout pregnancy, the first component involved longitudinal ASB 
screening of a cohort of low risk pregnant women in order to calculate the incidence 
rate of ASB at various gestational ages.  The second component, a cost-effectiveness 
analysis, used the incidence rates generated as probability estimates and evaluated the 
strategy of repeat screening for ASB in pregnancy.   In both components, the urine 
culture was used as the screening tool of choice for ASB.  
 
Screening 
Beginning September 2007, women with a documented pregnancy who presented for 
prenatal care at the Women’s Center at Yale-New Haven Hospital were invited to 
participate in the study.  The Women’s Center serves as a site of care for low risk 
obstetric patients; women with significant co-morbidites are referred to another facility 
for care by maternal-fetal medicine specialists. The study protocol was approved by the 
Human Investigation Committee at Yale University, and informed written consent was 
obtained for all subject participants.  Exclusion criteria were gestational age beyond 28 
weeks, insulin-requiring diabetes mellitus, sickle cell disease, chronic kidney disease, 
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and an inability to undergo the informed consent process in either English or Spanish.  
Women who were unable to provide at least two urine cultures, i.e. those who 
presented late in the second trimester, were also excluded from the study.  Study 
enrollment ended in April 2008, and ASB screening finished in August 2008. 
As per ACOG guidelines, an initial screening urine culture was obtained at the first 
prenatal visit.  All women were instructed how to perform a midstream clean catch.  At 
subsequent monthly prenatal visits, study participants were asked to provide clean 
catch urine for culture.  Screening continued until 28 weeks gestational age or until 
women developed true ASB, symptomatic urinary tract infection (UTI), or acute 
pyelonephritis; these scenarios all result in antibiotic treatment and have the potential 
to confound further screening cultures.   It was decided not to screen in the late third 
trimester as the most likely time for a second screening culture would be in the second 
or early third trimester as the vast majority of cases of pyelonephritis develop in these 
trimesters.   Gestational age was calculated using a woman’s last menstrual period 
(LMP) and verified by first or second trimester dating ultrasound; if there was inaccuracy 
in dating by LMP, dating was changed to reflect that estimated by ultrasound.   
All urine cultures were sent to the Yale-New Haven Hospital microbiology laboratory for 
processing and analysis.    Cultures obtained for the study were handled identically as 
those urine cultures collected for routine patient care; results were reported to 
clinicians in the usual fashion.  Outcome measures included the incidence of ASB in four 
week intervals as well as the incidence of pyelonephritis.  The incidence of ASB was 
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calculated based on the result of one urine culture with greater than 100,000 CFU/mL of 
at least one identified bacterial specimen, excluding lactobacillus.  The broad inclusion 
of many bacterial species was based on the description of microbiology of ASB by the 
IDSA; accordingly, bacterial species included within our definition were Escherichia coli, 
Klebsiella pneumonia, Proteus mirabilis, other Enterobacteriaceae, coagulative-negative 
staphylococci, Enterococcus, group B streptococci, Staphylococcus aureus, Streptococcus 
viridians, and Garnerella vaginalis.(1)  The incidence of pyelonephritis was calculated by 
the number of women diagnosed with acute pyelonephritis in pregnancy amongst our 
study population. It should be noted that the diagnosis of pyelonephritis was 
determined by the participant’s clinical care providers and validated based on 
documentation of two or more clinical findings (fever, flank pain, and costovertebral 
angle tenderness) in the medical record.  Secondary outcome measures were the rate of 
pre-term birth (less than 37 weeks GA) and low birth weight (less than 2,500 grams). 
Given the clear evidence that treatment for asymptomatic bacteriuria reduces the risk 
of pyelonephritis, all women found to have ASB were offered antibiotics and requested 
to provide a urine specimen for test of cure.  Decisions regarding the need for repeat 
urine cultures, further screening for bacteriuria, and need for antibiotic suppression 
were delegated to the participants’ clinicians.  Treatment of positive urine cultures that 
did not meet the criteria for ASB were deemed the responsibility of the patients’ 
clinicians; however, prior to the study’s commencement, all clinicians were provided 
with education about evidence-based criteria for ASB and encouraged to seek repeat 
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cultures for women with positive cultures that did not meet the 100,000 CFU/mL 
threshold.  Women who received antimicrobial agents during the study period were 
encouraged to provide urine for test of cure but they did not continue on the monthly 
screening regimen as antibiotics most likely altered the flora of their genitourinary tract.  
It should also be noted that the management of symptomatic UTI was determined by 
the participant’s primary provider.  A symptomatic UTI was defined as greater than 
>100,000 CFU on urine culture in the presence of common symptoms (i.e. dysuria, 
frequency, urgency, lower abdominal cramping).  Subjects with this diagnosis were not 
counted as cases of ASB. 
Patient characteristics such as gravidity, parity, age, history of diabetes mellitus, sickle 
cell trait, and history of previous urinary tract infections -- all factors known to influence 
the prevalence of ASB  -- were extracted from medical records.    
Descriptive statistics, incidence rates, and confidence intervals were calculated using 
SAS 9.1 and EXCEL.  Likewise, women with and without ASB were compared. 
 
Decision Analysis 
Using a decision tree model, three strategies were compared to evaluate the cost-
effectiveness of ASB screening in the prevention of pyelonephritis.  These strategies 
included (1) a policy of no screening, (2) a policy of screening for ASB once in the first 
trimester, and (3) a policy of screening for ASB once in the first trimester and once 
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between 18 and 22 weeks gestational age.   In the first strategy, no routine urine 
cultures were performed and women who had asymptomatic bacteriuria were left 
untreated. For the sake of the model, there were two opportunities for ASB, once in the 
first trimester and once in the second trimester. Given that unscreened women were 
asymptomatic, we assumed they were untreated and at high risk for pyelonephritis and 
ARDS.  In the second strategy, the current standard of care, women who entered 
prenatal care in the first trimester received one routine urine culture.  Similar to the first 
strategy, there were two opportunities for ASB and progression to pyelonephritis.  
Asymptomatic bacteriuria in the first trimester was treated with antibiotics and a test of 
cure was performed.  The risk of pyelonephritis due to first trimester ASB was 
significantly reduced by identification and treatment. A repeat screening urine culture 
was not performed in the 2nd trimester leaving an elevated risk of pyelonephritis similar 
to the first strategy.  The third strategy, our test strategy, allowed for routine urine 
cultures in the first and second trimester.  If ASB was identified in either case, it was 
treated and the risk of progressing to pyelonephritis was low.  In all cases, women with 
pyelonephritis were at risk of progressing to ARDS.  Furthermore, all women diagnosed 
with pyelonephritis received antibiotic treatment and chronic antibiotic suppression 
therapy for the remainder of the pregnancy.  
Figure 1 displays the schematic decision tree used in this analysis.  (For actual decision 
trees, see Appendix A-C.) 
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Figure 1. Schematic decision tree model comparing no screening, screening in the first 




Probability estimates  
The baseline probabilities were obtained after a thorough review of English medical 
literature and are summarized in Table 2.  We estimated the average prevalence of ASB 
among pregnant women in the first trimester to be 6%, a figure that represents the 
median value of previous prevalence estimates reported between 2-10%.(12, 41, 42)   
The risk of pyelonephritis among untreated bacteriuric women was estimated at 21%; 
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this risk was derived from a meta-analysis of 14 studies that involved 2302 women and 
reported the rate of progression from untreated ASB to pyelonephritis. The range of 
estimates for progression to pyelonephritis in this study was broad, from 2.5% to 
36%.(35)  The risk of pyelonephritis among women who were initially ASB-negative has 
been quoted in the literature to be 1-2%, and in the decision analysis we estimated the 
risk of progression to pyelonephritis among initially culture-negative women to be 
1%.(12, 13)    
For the purposes of this analysis, we assumed women enter prenatal care in the first 
trimester and that women identified with ASB are treated.   Antibiotic efficacy is 
reported to be 80-90% in clearing bacteriuria; thus, we made an assumption that 20% of 
women will have a positive follow-up urine culture and require suppressive therapy.(11, 
50)  Women with treated ASB have been reported to have an increased risk of 
pyelonephritis (0-17%), and thus like Rouse et al, we estimated their risk of progression 
to pyelonephritis to be 3% for both women requiring and not requiring antibiotic 
suppression.(35, 41)    
We deemed the inclusion of ARDS important as its risk of development provides, in part, 
the rationale for inpatient management of pregnant women with acute pyelonephritis.  
Approximately 2-8% of cases of acute pyelonephritis in pregnancy are complicated by 
respiratory insufficiency, and a recent prospective longitudinal study of women 
hospitalized for pyelonephritis in pregnancy reported that 7% (95% CI 5-10%) of women 
developed respiratory insufficiency.(19, 32, 33)   We used the estimate of 5% of women 
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with acute antenatal pyelonephritis develop ARDS in pregnancy and require admission 
to ICU.(19)  
For the policy of screening twice for ASB, we utilized data from our prospective cohort 
and estimated the prevalence of ASB at 18-22 weeks GA to be 3.4%.  The calculated 
incidence rate of ASB at 18-22 weeks was 4.21% (see Results section); however, we 
assumed that 80% of our incidence rate represented true bacteriuria as only one voided 
urine culture was used to define ASB.   Additionally, we estimated that the rate of ASB 
positivity on second trimester screen amongst women found to have ASB on the first 
trimester screen to be 25%.  The recurrence rate of bacteriuria in pregnancy is reported 
to be between 20 and 30%, and we used the median value for our baseline 
estimate.(14, 46, 50)  Our prospective cohort study was not powered to detect the 
incidence rate of pyelonephritis among women with two negative cultures.  However, 
3.0% of our study population developed ASB after two negative cultures, corresponding 
to a rate of 2.4% given the 80% probability of true bacteriuria with the use of a single 
culture.  From this statistic, we calculated a risk of pyelonephritis among women with 
negative first and second trimester ASB screening.  We predicted that women with two 
negative cultures who subsequently developed ASB would not be detected by the first 
and second trimester screening and thus would have a 21% risk of pyelonephritis. 
Therefore, we estimated that women with a negative first and second trimester screen 




Table 2. Baseline Estimates for Cost-Effectiveness Analysis 
Variable 
Baseline 
Estimate Range Reference 
ASB Prevalence    
Prevalence of ASB at 1
st
 TM (%) 6 2.0 - 10.0 12, 41, 42 
Prevalence of ASB at 2
nd
 TM (%) 3.4 0.9 – 8.6 n/a 
    
ASB progression to pyelonephritis    
Untreated ASB (%) 21 2.5 - 36 35 
Treated ASB (%) 3 0 - 17 35, 41 
After one negative culture (%) 1 1.0 - 2.0 1, 12, 13, 41 
After two negative cultures (%) 0.50 0 - 2 n/a 
    
Risk of recurrence    
ASB in 2nd TM after ASB in 1st TM (%) 25 20 - 30 14, 46, 50 
 
Risk of ASB after treatment in 1
st
 TM    
ASB in 2nd TM after treatment (%) 20 10 - 20 11, 50 
 
Risk of ARDS    




All costs are presented in 2008 US dollars.  For the analysis, published non-wholesale 
prices from www.drugstore.com were utilized for all medication costs, and other costs 
were drawn from the published literature (Table 3).  The cost of a 7-day course of 
antibiotics was derived from averaging the price of 3 different generic medication 
regimens (cephalexin, nitrofurantoin, and sulfamethoxazole-trimethoprim), as there is 
no single optimal antibiotic regimen for the treatment of ASB.  The cost of an antibiotic 
regimen was estimated to be $9.30.(51)   Approximately 10% of women treated for ASB 
are reported to develop vaginal candidiasis; the cost of a generic antifungal medication 
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for 1 week was $12.(51, 52)  Thus, the cost of antibiotic treatment for ASB was 
estimated to be $10.50 [$9.30 + (10% x $12)].   Those women with pyelonephritis as well 
as women with repeatedly positive cultures were assumed to require antibiotic 
suppression therapy for the duration of the pregnancy.   A common antibiotic regimen 
for suppression, 100 mg nitrofurantoin each night, was found to have a cost of $160 for 
a 20 week course or $8 per week.(51) 
Given that the treatment for ASB is empiric, only the cost of a urine culture without 
antibiotic sensitivities was needed; however, with increasing antibiotic resistance, many 
clinicians obtain antibiotic sensitivity at time of initial culture.  Urine culture cost was 
determined from 2008 Medicare data and encompassed the cost of urine culture, 
colony count, and antibiotic sensitivity.(53)  As mentioned earlier, pyelonephritis in 
pregnancy is often treated on an inpatient basis.  The costs to the patient and her family 
extend beyond the charges for hospitalization and treatment and include lost income 
and childcare; however, this analysis utilized only direct hospital costs.   In analysis of 
costs associated with acute pyelonephritis, Brown et al used an estimate of $6580 and 
$4312 for the direct costs associated with inpatient treatment of pyelonephritis with 
and without bacteremia, respectively.(54)  Taking into consideration that 20% of 
pregnant women with acute pyelonephritis are bacteremic at time of presentation, the 
cost estimate was $4698 [80% x $4312 + 20% x $6580] and was adjusted using the 
medical care component of the Consumer Price Index to reflect 2008 US dollars.(19, 41)  
Health care costs for ARDS are considerable because patients are almost exclusively 
27 
 
managed in an expensive ICU setting, with mean costs ranging from $48,000 to $73,000; 
we  used the conservative estimate of $48,000 for our analysis.(55-57)  We chose the 
lower estimate for our model as we assumed that most pregnant women are younger 
and healthier than many other patients admitted to the ICU with ARDS, thus most likely 
will require less care in comparison. 
 
Table 3. Cost Estimates for Decision Tree Model 
Variable 
Baseline 
Estimate ($) Range ($) Reference 
Screening    
Urine culture 11.79 10 - 55 53 
    
Antibiotic Therapy    
7-day course 10.50 7.80 – 57.60 51 
Suppression therapy 160 120-336 51 
    
Treatment of Acute Pyelonephritis    
Inpatient hospital costs 5795  3562-8117  19, 41 
 
Management of ARDS    





A baseline decision and cost analysis was performed using TreeAge Pro 2008 (TreeAge 
Software, Williamstown, MA).  Sensitivity analyses were subsequently done in 
recognition that our baseline estimates may not be applicable to all populations.  The 
decision analysis model was used to estimate the number of cases of pyelonephritis and 
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ARDS that would occur with no screening, a first trimester screening culture only, and 
both a first and second trimester screening.  Calculated costs of each strategy 
encompassed ASB screening and treatment costs as well as costs of inpatient treatment 
of acute pyelonephritis and ARDS.  Costs of the one culture strategy and two culture 
strategy were compared to that of the no screening strategy. Incremental savings of 
1st/2nd trimester urine cultures were calculated by subtracting expected costs of the 




Prospective Cohort Study 
Of the 250 women invited to participate in the study, 206 women comprised the study 
population, representing an acceptance rate of 82.4%.  Of those, over 90% provided at 
least two urine cultures during the screening period, and over 70% provided at least 
three ASB screening cultures.  Figure 2 shows detailed information on enrollment and 
retention. 















250 women invited to participate 
206 women eligible and 
consented to participation 
(82.4% acceptance rate) 
192 women provided at least 
2 urine cultures for ASB 
screening    
(93.2% retention rate) 
44 women ineligible or did 
not consent to participate 
Beyond 28 weeks GA (n=5) 
Language barrier (n=8) 
Refused to participate 
(n=31) 
14 women provided 1 urine culture 
for ASB screening 
Lost to follow-up (n=5) 
Spontaneous abortions (n=2) 
Patient refusal (n=2) 
Missed appointments (n=4) 




The mean age of participants was 24.3 years (SD 5.3). Forty-two percent were African-
American, and 48.5 percent were Hispanic.  Most women were multiparous (median 
gravidity and parity of 2 and 1, respectively).  Only 7.8% of the study cohort possessed 
one or more known risk factors for ASB. (i.e. diabetes mellitus, sickle cell trait, history of 
pyelonephritis).  The vast majority of subjects carried singleton gestations; there was 
one twin gestation.  During the study period, there were a total of 27 cases of ASB. 
There were no significant differences in demographic and clinical characteristics 
between women with and without ASB, with the exception that women with ASB were 
more likely to have a documented history of urinary tract infection (Table 4).       
 
Table 4. Selected demographic and clinical characteristics of women with ASB compared 
with women without ASBD  
  
Women positive for 
ASB (N=27) 
Women negative for 
ASB (N=179) 
p-value 
Mean Age 22.6(5.4) 23.4(5.2) 0.587 
Median Gravidity 3 (2-4) 2 (2-3) 0.205 
Median Parity 1 (0-2) 1 (0-2) 0.772 
Race/Ethnicity   0.596 
African-American 10 (37.0) 74 (42.8)  
Caucasian 14 (51.9) 84 (48.6)  
Hispanic 2 (7.4) 13 (7.5)  
Other 1 (3.7) 2 (1.2)   
Patients with presence of at least 
one  known risk factor of ASB 
5 (18.5) 12 (6.7) 0.053 
Diabetes mellitus 1 (3.7) 0 (0) 0.52 
History of Pyelonephritis 1 (3.7) 5 (2.8) 0.136 
Immunosuppression 1 (3.7) 0 (0) 0.52 
Sickle cell trait 2 (7.4) 3 (1.7) 0.523 
Documented history of UTI 7 (25.9) 17 (9.8) 0.026 
Current Smoking 5 (18.5) 18 (10.4) 0.208 
D
Continuous variables expressed as mean + SD. Comparisons made using Student t test. 
Categorical variables expressed as number of patients(%). Comparisons made using Fisher’s exact test. 




The mean gestational age at ASB detection was 15.0 (SD 5.5) weeks.  The prevalence 
rate of ASB was 8.93% at less than 10 weeks GA, 5.6% between 10-14 weeks GA, 4.1% 
between 14-18 weeks GA, 6.60% between 18-22 weeks GA, and 2.61% at greater than 
21 weeks GA.    Among women who developed ASB, 18.5% had one known risk factor 
compared to 6.7% of women who did not develop ASB during the study period, a 
difference that was not statistically significant (See Table 4).   Moreover, women with 
known risk factors for ASB were not more likely to develop ASB throughout gestation in 
comparison to women without such risk factors (see Table 5). 
   
Table 5.  Number of women with and without known risk factors who developed ASB by 
gestational ageE 
Gestational age window 
Women with risk factors 
(N=16) 
Women without risk 
factors (N=190) 
p-value 
<10 wks 1 5 0.918 
10-14 wks 1 5  
14-18 wks 0 5  
18-22 wks 2 6  
>22 wks 0 2  
E
Risk factors include sickle cell trait, non-insulin requiring diabetes mellitus, immunosuppression, and 
history of pyelonephritis 
 
As shown in Table 6, the predominant organism was Escherichia coli, accounting for 41% 
of all cases of ASB.  The next most common uropathogen was group B Streptococcus and 
other gram positive organisms.  Notably amongst all ASB bacterial isolates with  
documented sensitivities, 66.7% were resistant to at least one antibiotic agent, and 
ampicillin resistance in E coli was found to be 36.4%.   
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Table 6.  Frequency of uropathogens in ASB-documented urine culturesF 
Urine Culture Results   
Escherichia coli 11 (41) 
Klebsiella-Enterobacter group 4 (15) 
Proteus species 2 (7) 
Enterococcus species 3 (11) 
Group B streptococcus and other 
gram positive organisms 
7 (26) 
Total 27 (100) 
F
Data reported as number of patients(%). 
 
Of note, there were additional positive cultures with colony counts below 100,000 that 
did not meet the study’s definition of ASB.   The prevalence rates of any positive urine 
culture are reported in Table 7; like the trend seen amongst all cases of ASB, the 
observed prevalence rates peak in the gestational age windows of 10-14 weeks and 18-
22 weeks.   
 
Table 7.  Prevalence of ASB by gestational age for all cases of ASB and among women 
who were initial culture-negative and prevalence of any positive urine culture by 
gestational age.G 
 Gestational age window 




True ASB among initial 
culture-negative women  
> 10 to 14 weeks GA 5.6% (2.3- 11.5%) 10.4% (5.5- 17.8%) 0% (0 – 16.8%) 
>14 weeks to 18 weeks GA 4.1% (1.3 – 9.6%) 6.6% (2.8 – 12.9%) 1.1% (0 - 6.3%) 
>18 weeks to 22 weeks GA 6.6% (2.7 - 13.6%) 11.3% (5.8 - 19.8%) 4.2% (1.1 – 10.8%) 
> 22 weeks GA 2.6% (0.5 - 7.6%) 2.6% (0.5 – 7.6%) 1.8% (0.2 – 6.4%) 
G
Data shown as estimates (95% Confidence Interval)  
 
 
The prevalence of ASB at initial culture was 9.71%, and the mean gestational age at the 
time of this culture was 12 weeks (SD 3.5).  Given the use of one culture to define ASB, 
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and the results of Kass et al. suggesting that 80% of cultures growing 100,000 colonies 
are confirmed positive upon repeat culture, we calculated an adjusted prevalence rate 
to be 7.77%.(8, 10) 
 
Figure 3. Analysis using McNemar statistic for 
the number of women identified with ASB on 







The proportion of women identified with ASB on initial culture did not differ statistically 
from the proportion identified by later cultures during gestation (McNemar’s test, p-
value > 0.05; Figure 3).   For those women who did not have bacteriuria on initial 
culture, the incidence rate of ASB in the remainder of the study was 4.34% (95% CI 1.75 
– 8.96%).    Among women with an initial negative urine culture, the incidence rate of 
ASB was 0% up to 14 weeks GA (95% CI 0.0– 16.8%), 1.1% between 14 and 18 weeks GA 
(95% CI 0.0 – 6.3%), 4.2% between 18 and 22 weeks GA (95% CI 1.1– 10.8%), and 1.8% 
beyond 22 weeks GA (95% CI 0.2 – 6.4%)(Figure 4).  The mean gestational age of ASB 
detection was 20.5 (SD 2.9) weeks for initially culture-negative women.  Interestingly, 
among all women who had at least 2 documented negative urine cultures (N= 134), only 
4 developed ASB, a rate of ASB of 3.00% (95% CI 0.81 – 7.64 %). 
 
   




ASB - ASB + 
 
ASB - 165 8 173 
ASB + 15 4 19 




Figure 4.  Incidence rate of ASB among women with initial negative culture 
 
 
Of note, there were 11 documented symptomatic urinary tract infections, 8 of which 
were uncomplicated cases of cystitis.  E coli was the most common organism 
responsible for symptomatic UTIs, accounting for 63.6% of such infections.   Three cases 
of acute pyelonephritis were diagnosed amongst the study population, resulting in an 
incidence rate of 1.46% or 14.6 per 1000 pregnancies.  All episodes of pyelonephritis 
occurred in the second trimester and at average gestational age of 19.8 weeks GA 
(SD=0.3).  Diagnosis of pyelonephritis was based on clinical findings of fever 
(temperature>38°C) (n=2), flank pain (n=3), and costovertebral angle tenderness (n =2).  
Analysis of urine revealed bacteriuria with > 100,000 CFU/mL in 66.7% (n=2) of cases 
and pyuria (>5 leukocytes per HPF) in 100% (n=3) of cases.  All women with symptomatic 
urinary tract infections received antibiotic therapy.  No woman required admission to 
the intensive care unit while receiving inpatient treatment for pyelonephritis. Of note, 
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one of the three women diagnosed with acute pyelonephritis had previous successful 
treatment for uncomplicated cystitis; another woman, with known poorly controlled 
HIV, was diagnosed with asymptomatic bacteriuria but never received treatment, and 
the third woman did not have any positive urine cultures throughout gestation, 
including at the time of diagnosis for pyelonephritis. 
Amongst our study population, there were 21 cases of preterm birth, comprising 11.4% 
of all documented births.  Of these preterm deliveries, 42.9% resulted from 
spontaneously preterm birth, and the remainder resulted from obstetric intervention 
for maternal or fetal indications.  The rate of low birth weight, infants less 2500 grams, 
was 4.4%; however if gestational age is considered, the rate of small for gestational age 
infants was only 1.65%.  Amongst women with ASB, there were 4 cases of preterm 
delivery, of which only one was the result of spontaneous preterm labor, and there 
were no small-for-gestational age infants.   The rate of preterm delivery or low birth 
weight amongst women with bacteriuria did not differ significantly from the rate 




Table 8 shows the costs of each screening strategy, and notably total direct costs were 
the lowest with the 1st and 2nd trimester screening policy, while the no screening policy 
had the highest total costs.    





Routine 1st trimester 
screening 
1st and 2nd trimester 
screening 
Costs of ASB screening and 
treatment ($) 
0 1,242,000 2,465,000 
    
Costs of acute care 
(pyelonephritis and ARDS) ($) 
22,303,000 13,334,000 6,777,000 
    
Total expected costs ($) 22,303,000 14,576,000 9,242,000 
 
Table 9 demonstrates the results of the base-case analysis comparing the no screening 
strategy to first trimester and first/second trimester urine culture screening strategies.   
A hypothetical cohort of 100,000 pregnant women was used to illustrate the differences 
in the results more clearly.  With a policy of no screening, our model predicts a rate of 
pyelonephritis of 26.7 per 1000 pregnancies.  With no screening, there are significantly 
more cases than predicted for the single urine culture strategy (16 per 1000 
pregnancies) and the two urine culture strategy (8.1 per 1000 pregnancies).  Reductions 
in the incidence of more significant maternal outcomes such as ARDS are also noted 
with a two urine culture strategy from 133 expected cases (no screening) to 41 expected 
cases (two culture strategy).   
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Although costs associated with increased screening for and treatment of asymptomatic 
bacteriuria result in greater initial expense with the one and two urine culture strategies 
compared to no-screening, these costs are small compared to the expected savings from 
avoiding in-patient care for pyelonephritis and acute respiratory distress syndrome.  
Table 9. Results summary for baseline estimates (per 100,000 patients) 




1st and 2nd 
trimester 
screening 
Expected cases of 
pyelonephritis (#) 
2,669 1,596 811 
 Pyelonephritis prevented  (#) 
(vs. no screening) 
--- 1,073 1,858 
    
Expected cases of ARDS (#) 133 80 41 
  
ARDS prevented (#) 
(vs no screening)  
--- 53 92 
    
Expected costs of strategy  $22,303,000 $14,576,000 $9,242,000 
 
Cost savings 
(vs no screening) 
 
--- $7,727,000 $13,061,000 
 Incremental cost savings  
(vs 1st TM screening) 
--- --- $5,334,000 
 
Unlike most additional screening tests which introduce increased expenses in order to 
improve health, an additional urine culture is predicted to not only reduce the risk of 
adverse maternal outcomes (by preventing pyelonephritis and ARDS), but is also 
expected to bring substantial cost savings. As such, there is no true cost per 
pyelonephritis prevented.  Rather costs saved are in addition to cases of pyelonephritis 
prevented. This is the case when routine first trimester screening is compared to a no-
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screening strategy.  The improved health states and costs are magnified with a repeat 
urine culture in the 2nd trimester (i.e. 18-22 weeks GA). 
A series of univariate sensitivity analyses were performed, changing the baseline 
probabilities and cost estimates across their plausible ranges.  The repeat screening 
strategy remained the dominant strategy over both single screening and no screening 
strategies, except with regard to two variables.  The cost-effectiveness of repeat 
screening was affected by the risk of progression to acute pyelonephritis among 
untreated bacteriuric women.  When the risk of pyelonephritis was less than 4% (base 
case 21%), the two urine culture strategy no longer dominated the other two strategies 
and became more expensive than the single urine culture strategy. However, at this 
threshold, the two urine culture strategy continued to be the strategy that maximized 
maternal outcomes. In fact, when the probability of pyelonephritis in the untreated 
woman was reduced to 2.5% the cost to prevent one case of pyelonephritis with this 
strategy (compared to one urine culture strategy) would be $4,664. In addition, when 
the cost of a urine culture exceeded $65, screening in the first and second trimester was 
no longer the dominant strategy.   The single screening strategy became the cheapest 
policy when the cost of the urine culture was between $65 and $89, while the no 
screening strategy had the lowest overall cost when the urine culture exceeded $89.  If a 
urine culture costs $100, the cost to prevent one case of pyelonephritis with this 2 
culture strategy (compared to one urine culture strategy) would be $4,423.  
Nonetheless, for any urine culture cost, the 1st and 2nd screening strategy remained the 




Throughout the literature, it is reported that the incidence rate of ASB after an initial 
negative urine culture did not exceed 1-2%; however, the incidence of pyelonephritis 
amongst this same cohort of women was cited to be also between 1-2%.   Closer 
analysis of these statistics raised the possibility that more women were becoming 
bacteriuric than the literature from the 1950s and 1960s suggested. Amongst our 
prospective cohort of women seeking prenatal care, a greater proportion of women 
developed ASB after a negative first urine culture in comparison to reports in the 
literature.  The overall calculated incidence rate of ASB through 28 weeks GA amongst 
such women was 4.3% (95% CI 1.75 – 8.96%).   This incidence rate may be 
underestimated as positive cultures with less than 100,000 CFU/mL were excluded from 
ASB calculations. Notably, women with known risk factors (i.e., diabetes mellitus, sickle 
cell trait, and immunosuppression) for ASB did not develop ASB at significantly 
increased rates in comparison to women without such risk factors – a finding that 
suggests that targeted screening of women with identifiable risk factors will not lead to 
increased detection of ASB.   
Although our cohort did not have excess risk factors for ASB, its other characteristics, 
namely multiparity and low socio-economic status, have been associated with increased 
ASB prevalence.  Despite the fact that the population prospectively followed was 
predicted to have a greater risk of ASB, the rate of ASB on initial culture was consistent 
with previously reported rates.  The prevalence rate of ASB at initial culture, adjusted 
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for the use of a single diagnostic culture, was 7.7%.  This prevalence falls within the 
range of ASB prevalence reported across various obstetric populations.   
Like previous studies, we found E coli to be the predominant pathogen responsible for 
ASB.   Interestingly, gram-positive organisms comprised a larger percentage of 
bacteriuria cases than prior studies have indicated.   Hill et al, in a recent prospective 
longitudinal study of acute pyelonephritis, found that the frequency of gram-positive 
organisms doubled by the third trimester and such pathogens accounted for an 
increasing proportion of cases of acute pyelonephritis.(19)   As a result of screening 
from the first prenatal visit until early in the third trimester, our data may have captured 
this shift in microbiology from predominantly gram-negative organisms to more gram-
positive organisms.   It is possible that a single screening in early pregnancy may miss 
the detection of gram-positive organisms that appear later in gestation. 
Interestingly, the development of ASB, after a negative culture, occurred most often in 
the window between 18 and 22 weeks gestational age.  This peak in ASB incidence, 
albeit not statistically significant, was seen also amongst all cases of ASB and amongst 
any positive culture. This increase in incidence in the 18 to 22 week GA interval has 
biological plausibility.  It occurs as the enlarging uterus extends beyond the pelvis, 
compressing the ureters, and as the placenta continues its increasing production of 
progesterone, physiologic changes that may predispose women to greater urinary stasis 
and bacterial proliferation.   Moreover, as women engage in sexual activity throughout 
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pregnancy, bacteria will be introduced in the sterile urinary tract and changes of 
pregnancy may contribute to enhanced bacterial growth.    
As most cases of pyelonephritis occur in the second and third trimester, the goal of any 
screening program would be to identify cases of ASB before their progression to 
symptomatic infection; the mid-trimester peak in our study suggests a logical time for a 
second screening urine culture in pregnancy.  Larger studies will be required to 
determine if this peak in incidence at 18-22 weeks will be replicated in other 
populations.  In a cohort of 1050 women, McIsaac and colleagues (2005) reported that a 
single culture early in pregnancy failed to identify more than half of the cases of ASB, 
concluding that additional cultures are required; however, they made no assessment of 
the impact of increased ASB detection on incidence of acute pyelonephritis in 
pregnancy.  Larger randomized controlled trials would help to resolve the question as to 
whether repeat screening decreases the incidence of pyelonephritis as the true 
objective is to prevent additional cases of pyelonephritis that would be missed by a 
single culture strategy.    
Our study did not have sufficient power to compare the incidence of pyelonephritis 
between a repeat screening strategy and a single culture strategy.  Nonetheless, the 
incidence rate of pyelonephritis in our study was 1.5%, consistent with the published 
incidence rate of  pyelonephritis in pregnancy of 1-2%.(19, 21)  Interestingly, there was 
only one case of acute pyelonephritis amongst all women with ASB; this woman was 
non-adherent to her antibiotic regimen in addition to being immunosuppressed.  There 
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were no significant associations between bacteriuria and low birthweight or preterm 
birth, 
Like Rouse et al, we found that use of a single urine culture for ASB screening in 
pregnancy was cost-saving in comparison to no screening.  Furthermore, our study 
demonstrates that repeat ASB screening and treatment is also cost-effective in 
comparison to a no screening strategy and to the standard one urine culture strategy, 
and provides a strong case for the multiple screening strategy.  It should be noted that 
our cost estimates most likely represented an underestimation of the total costs as we 
only considered direct hospital costs.  The sensitivity analyses revealed the dominance 
of repeat screening over the alternative strategies for almost every plausible probability 
value and cost estimate.  These results can be attributed to the relatively low cost of 
urine cultures in pregnancy compared to high costs of inpatient management of acute 
pyelonephritis in pregnancy.  Some researchers have suggested that uncomplicated 
pyelonephritis can be treated effectively and safely on an outpatient basis; however, the 
relatively high rate of complications arising in pregnant women with pyelonephritis 
(respiratory insufficiency, need for intensive care unit admission, and septicemia) will 
limit the widespread implementation of outpatient management and maintain the 
relatively high costs of acute antepartum pyelonephritis.(58)   
The variables that most affected the cost-effectiveness outcome are the cost of urine 
culture and the risk of progression of untreated ASB to acute pyelonephritis.  
Understandably when the screening tool, namely the urine culture, becomes too 
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expensive, then screening, and in this case repeat screening, is no longer cost-saving.  
Likewise when the risk of pyelonephritis among untreated bacteriuric women is lower, 
the benefit of ASB screening becomes less.  Nonetheless, the two urine culture strategy 
continued to be the strategy that maximized maternal outcomes across all costs and 
probability estimates.  
We recognize that the multiple screening strategy has its drawbacks.  Obtaining urine 
for culture in all prenatal patients can add additional work to busy obstetric practices.  
Providers will be required to follow-up cultures results, prescribe appropriate 
antibiotics, and perform repeat cultures as tests of cure.  Importantly, there is concern 
that inappropriate antibiotic use will lead to increasing antibiotic resistance.  There are 
no current treatment recommendations for cultures with less that 100,000 CFU/mL as 
there are unclear implications of lower colony counts in pregnancy.  In the absence of 
guidelines around lower colony counts, we found that physicians and midwives were 
using antimicrobial agents to treat urine cultures that did not meet the criteria for ASB 
due to concerns about the risks of untreated bacteriuria in pregnancy.  In our study, a 
high rate of antibiotic resistance was observed among E coli and other pathogens, a 
finding that is consistent with reports in the literature.(35)  Moreover, antibiotics have 
adverse effects including gastro-intestinal upset, Clostridium difficile infection, allergic 
reactions, and the development of symptomatic yeast infections.    Yet despite these 
concerns regarding antibiotic use, our analysis strongly demonstrates that repeat 
screening offers the dual benefit of preventing additional cases of pyelonephritis and 
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decreasing overall health care costs.   Any implementation of a multiple ASB screening 
strategy would require guidelines and provider education about appropriate antibiotic 
use in the care of pregnant women. 
There are several limitations to our study.  Our study cohort was mostly multiparous 
women of color with lower than average socioeconomic status, a population that may 
not reflect a typical obstetric practice.  The estimate of ASB prevalence on repeat 
culture after an initial negative culture used in the cost analysis was derived from this 
cohort, and thus may not be universally applicable to antepartum populations.  
Moreover, the peak incidence of ASB after an initial negative culture was not statistically 
different than the other four week gestational age windows studied, and a larger sample 
size may be needed in order to detect differences in ASB incidence rates in four week 
intervals and to determine the most optimal time to perform a second urine culture.   In 
addition, the frequent treatment of urine cultures that did not meet criteria for ASB 
most likely led to an underestimation of the true rate of ASB on repeat culture.   
Nonetheless, this study is one of the few to evaluate repeat ASB screening and 
treatment in the prevention of pyelonephritis in pregnancy. The strength of the analysis 
lies in the persistence of the cost-benefit findings of repeat screening over a wide range 
of probabilities and costs.  Before implementation of a repeat screening policy, larger 
studies will be needed to determine if screening in both first and second trimesters can 
indeed reduce the incidence of acute antepartum pyelonephritis. If multiple cultures are 
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shown to decrease this incidence rate, our results offer strong evidence for the benefits 






PROBABILITIES   
pARDS probability of ARDS 
pASB1TM probability of ASB in first trimester 
pASB2TM probability of ASB in second trimester 
pASBpersistent probability of persistent ASB 
pASBrecurrence probability of ASB recurrence after treatment 
pPyelo1NegCx probability of pyelonephritis with 1 negative screening culture 
pPyelo2NegCx probability of pyelonephritis with 2 negative screening cultures 
pPyeloASBRx probability of pyelonephritis after ASB treatment 
pPyeloNoRx probability of pyelonephritis with untreated ASB 
pRx probability of treatment 
pRxNoScreen probability of treatment with no screening 
  
COSTS   
cARDS cost of inpatient ARDS management 
cASBTreatment cost of ASB treatment 
cNoScreen cost of no screening 
cPyelo cost of inpatient management of acute pyelonephritis 
cSuppression cost of antibiotic suppression 
cUCx cost of urine culture 
  
UTILITIES   
uARDS utility of ARDS 
uHealthy utility of "healthy" 
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